188 related articles for article (PubMed ID: 28208074)
21. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.
Tseng D; Volkmer JP; Willingham SB; Contreras-Trujillo H; Fathman JW; Fernhoff NB; Seita J; Inlay MA; Weiskopf K; Miyanishi M; Weissman IL
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11103-8. PubMed ID: 23690610
[TBL] [Abstract][Full Text] [Related]
22. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
23. Porcine signal regulatory protein alpha binds to human CD47 to inhibit phagocytosis: Implications for human hematopoietic stem cell transplantation into severe combined immunodeficient pigs.
Boettcher AN; Cunnick JE; Powell EJ; Egner TK; Charley SE; Loving CL; Tuggle CK
Xenotransplantation; 2019 Mar; 26(2):e12466. PubMed ID: 30311702
[TBL] [Abstract][Full Text] [Related]
24. Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.
Buatois V; Johnson Z; Salgado-Pires S; Papaioannou A; Hatterer E; Chauchet X; Richard F; Barba L; Daubeuf B; Cons L; Broyer L; D'Asaro M; Matthes T; LeGallou S; Fest T; Tarte K; Clarke Hinojosa RK; Genescà Ferrer E; Ribera JM; Dey A; Bailey K; Fielding AK; Eissenberg L; Ritchey J; Rettig M; DiPersio JF; Kosco-Vilbois MH; Masternak K; Fischer N; Shang L; Ferlin WG
Mol Cancer Ther; 2018 Aug; 17(8):1739-1751. PubMed ID: 29743205
[TBL] [Abstract][Full Text] [Related]
25. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.
Herbst R; Wang Y; Gallagher S; Mittereder N; Kuta E; Damschroder M; Woods R; Rowe DC; Cheng L; Cook K; Evans K; Sims GP; Pfarr DS; Bowen MA; Dall'Acqua W; Shlomchik M; Tedder TF; Kiener P; Jallal B; Wu H; Coyle AJ
J Pharmacol Exp Ther; 2010 Oct; 335(1):213-22. PubMed ID: 20605905
[TBL] [Abstract][Full Text] [Related]
26. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
[TBL] [Abstract][Full Text] [Related]
27. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
Sim J; Sockolosky JT; Sangalang E; Izquierdo S; Pedersen D; Harriman W; Wibowo AS; Carter J; Madan A; Doyle L; Harrabi O; Kauder SE; Chen A; Kuo TC; Wan H; Pons J
MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
[TBL] [Abstract][Full Text] [Related]
28. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.
Liu X; Pu Y; Cron K; Deng L; Kline J; Frazier WA; Xu H; Peng H; Fu YX; Xu MM
Nat Med; 2015 Oct; 21(10):1209-15. PubMed ID: 26322579
[TBL] [Abstract][Full Text] [Related]
29. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
Gholamin S; Mitra SS; Feroze AH; Liu J; Kahn SA; Zhang M; Esparza R; Richard C; Ramaswamy V; Remke M; Volkmer AK; Willingham S; Ponnuswami A; McCarty A; Lovelace P; Storm TA; Schubert S; Hutter G; Narayanan C; Chu P; Raabe EH; Harsh G; Taylor MD; Monje M; Cho YJ; Majeti R; Volkmer JP; Fisher PG; Grant G; Steinberg GK; Vogel H; Edwards M; Weissman IL; Cheshier SH
Sci Transl Med; 2017 Mar; 9(381):. PubMed ID: 28298418
[TBL] [Abstract][Full Text] [Related]
30. CD47 is required for suppression of allograft rejection by donor-specific transfusion.
Wang H; Wu X; Wang Y; Oldenborg PA; Yang YG
J Immunol; 2010 Apr; 184(7):3401-7. PubMed ID: 20208011
[TBL] [Abstract][Full Text] [Related]
31. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.
Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW
Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508
[TBL] [Abstract][Full Text] [Related]
32. Anti-CD47 antibody synergizes with cisplatin against laryngeal cancer by enhancing phagocytic ability of macrophages.
Wang J; Zhang H; Yin X; Bian Y
Clin Exp Immunol; 2021 Sep; 205(3):333-342. PubMed ID: 33999416
[TBL] [Abstract][Full Text] [Related]
33. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
34. Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis.
Kamber RA; Nishiga Y; Morton B; Banuelos AM; Barkal AA; Vences-Catalán F; Gu M; Fernandez D; Seoane JA; Yao D; Liu K; Lin S; Spees K; Curtis C; Jerby-Arnon L; Weissman IL; Sage J; Bassik MC
Nature; 2021 Sep; 597(7877):549-554. PubMed ID: 34497417
[TBL] [Abstract][Full Text] [Related]
35. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
36. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
[No Abstract] [Full Text] [Related]
37. Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice.
Han MH; Lundgren DH; Jaiswal S; Chao M; Graham KL; Garris CS; Axtell RC; Ho PP; Lock CB; Woodard JI; Brownell SE; Zoudilova M; Hunt JF; Baranzini SE; Butcher EC; Raine CS; Sobel RA; Han DK; Weissman I; Steinman L
J Exp Med; 2012 Jul; 209(7):1325-34. PubMed ID: 22734047
[TBL] [Abstract][Full Text] [Related]
38. Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation.
Hatterer E; Barba L; Noraz N; Daubeuf B; Aubry-Lachainaye JP; von der Weid B; Richard F; Kosco-Vilbois M; Ferlin W; Shang L; Buatois V
MAbs; 2019; 11(2):322-334. PubMed ID: 30569825
[TBL] [Abstract][Full Text] [Related]
39. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.
Chao MP; Tang C; Pachynski RK; Chin R; Majeti R; Weissman IL
Blood; 2011 Nov; 118(18):4890-901. PubMed ID: 21828138
[TBL] [Abstract][Full Text] [Related]
40. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.
Edris B; Weiskopf K; Volkmer AK; Volkmer JP; Willingham SB; Contreras-Trujillo H; Liu J; Majeti R; West RB; Fletcher JA; Beck AH; Weissman IL; van de Rijn M
Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6656-61. PubMed ID: 22451919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
